Category : Clinical Research, Pharma & Healthcare Financing

Incuvio, a healthcare consulting and technology solutions firm, announced its acceptance into the Association for Community Affiliated Plans (ACAP) Preferred Vendor Program. The strategic partnership...

Pivotal trial evaluated the safety and efficacy of the Hēlo™ Thrombectomy System for the removal of blood clots from the lungs Dr. Andrew Klein, ENGULF National...

Phase III ALLEGORY study met primary and all key secondary endpoints with Gazyva, an anti-CD20 monoclonal antibody designed for enhanced B cell depletion Gazyva has...

Shanghai Ark Biopharmaceutical Co., Ltd. (“ArkBio”) today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent...

Phase Ib/IIa study found VES001, the first oral therapy being tested in FTD, led to >95% mean increase in progranulin levels in CSF, compared to baseline...

ProImmune Ltd, a global leader in life science reagents and services, today announced the launch of its new ProVE® SL Self-Loading MHC Class I Monomers. The novel...

Lantern Pharma Inc. (NASDAQ: LTRN)— Lantern today announced it will present two commercially deployed AI research platforms at the inaugural AI for Biology and Medicine...

Pinetree Therapeutics, a preclinical-stage biotechnology company pioneering targeted protein degraders for drug-resistant cancers, announced the successful closing of an oversubscribed $47 million Series B financing....

Trial will evaluate the safety and effectiveness of the AtriCure Isolator® Synergy™ EnCompass® clamp and AtriClip® Left Atrial Appendage Exclusion System to reduce the occurrence of new-onset atrial...

PetPace, the leading provider of smart wearable health monitoring collars for animals and Crucial Data Solutions, Inc. (CDS), the pioneer behind the end-to-end eClinical platform TrialKit,...

PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable...

Phase 3b LUCENT-URGE is the first study in inflammatory bowel disease to assess bowel urgency across three measures — severity, frequency and stool deferral time...

GSK plc (LSE/NYSE: GSK) today announced the US Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone (BVd) for the...

Publication illustrates foundational innovation that has defined the company’s advanced platform integrating high-dimensional transcriptomics and AI predictive modeling for drug discovery Cellarity, a biotechnology company...

Electra Therapeutics is a late-stage biotechnology company developing new medicines for people with serious immunological and cancer-related diseases Financing was co-led by EQT Life Sciences...